Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05156060 · ClinicalTrials.gov registry record · Phase 1
Gabapentin & Ketamine for Prevention/Treatment of Acute/Chronic Pain in Locally Advanced Head and Neck Cancer
A Phase 1 study of Head and Neck Cancer and Locally Advanced Head and Neck Carcinoma, sponsored by Natalie Lockney.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 64
- Enrollment target
- 1
- Study location
NCT05156060: Recruiting Phase 1 study of Head and Neck Cancer and Locally Advanced Head and Neck Carcinoma, sponsored by Natalie Lockney.
NCT05156060 is a Phase 1 study of Head and Neck Cancer and Locally Advanced Head and Neck Carcinoma that is actively recruiting participants, run by Natalie Lockney. The registered enrollment target is 64 participants, below the 261-participant average among 250 other Head and Neck Cancer trials with a reported enrollment target (75% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05156060, a Phase 1 study of Head and Neck Cancer and Locally Advanced Head and Neck Carcinoma, is actively recruiting participants, sponsored by Natalie Lockney.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 64 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a study to establish a safe and feasible dose for prophylactic use of a combination of gabapentin and ketamine in head and neck cancer patients undergoing chemoradiation.
Primary Outcome
Up to a maximum planned dose of 40 mg three times a day
Conditions Studied
Interventions
- DRUG Ketamine
- DRUG Gabapentin
Study Locations (1)
Tennessee
- Vanderbilt-Ingram Cancer Center - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2022-01-24 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 1 |
What NCT05156060 shows while recruiting
NCT05156060 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 64 participants, a relatively small participant target, below the 261-participant average among 250 other Head and Neck Cancer trials with a reported enrollment target (75% lower).
The record links to 2 conditions, with Head and Neck Cancer appearing as the primary indexed condition, and to 2 interventions - of which Ketamine is the first listed.
NCT05156060 reports a single indexed study location in Tennessee.
Frequently Asked Questions
What is clinical trial NCT05156060 about?
NCT05156060 is a clinical study titled "Gabapentin & Ketamine for Prevention/Treatment of Acute/Chronic Pain in Locally Advanced Head and Neck Cancer". This is a study to establish a safe and feasible dose for prophylactic use of a combination of gabapentin and ketamine in head and neck cancer patients undergoing chemoradiation.
What is the current status of trial NCT05156060?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 64 participants. The study started on 2022-01-24. Estimated completion is 2026-12-31.
What conditions does trial NCT05156060 study?
This clinical trial studies the following conditions: Head and Neck Cancer, Locally Advanced Head and Neck Carcinoma.
What interventions are being tested in trial NCT05156060?
The interventions under investigation include: Ketamine (DRUG), Gabapentin (DRUG).
Who is sponsoring clinical trial NCT05156060?
This trial is sponsored by Natalie Lockney, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05156060 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Head and Neck Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05156060's enrollment target sits among peer trials
64 112th of 250 higher than 138 of 250 other Head and Neck Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Head and Neck Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Cancer
RECRUITING · Phase 1
-
RAPA-201 Therapy of Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
RECRUITING · Phase 1
-
Autologous CAR-T Cells Targeting CSPG4 in Relapsed/Refractory HNSCC
RECRUITING · Phase 1
-
TheraT® Vectors (Vaccines) Combined With Chemotherapy to Treat HPV16 Head and Neck Cancers
RECRUITING · Phase 1
-
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01853631 · 64 participants · Phase 1
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
- NCT03739502 · 64 participants · Phase 2
A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant
- NCT03739814 · 64 participants · Phase 2
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
- NCT03866408 · 64 participants · Early Phase 1
Insulin Regulation of Lipolysis and Lipolysis Proteins
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI